Break it Down: LTR Pharma prescribes ED spray under TGA scheme

Stockhead’s Break it Down brings you today’s leading market news in under 90 seconds.

In this episode, host Sarah Hughan tells all on LTR Pharma (ASX:LTP) prescribing its Spontan formulation to patients for the first time under the Therapeutic Goods Administration’s Special Access Scheme.

Spontan was created to achieve optimal sexual function by assisting erectile dysfunction (ED).

Tune in to get the latest.

While LTR Pharma is a Stockhead advertiser, it did not sponsor this content.